Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $0 a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 net receivables of $0 is the 7th highest of the 11 companies compared; the peer median is $6.12M.
- Net receivables amounts to 0.0% of total assets for NVCT, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $60.69M | +182.5% | +158.8% | 12.8% | |
| Mar 2026 | $42.46M | +660.3% | +109.4% | 4.1% | |
| Jun 2026 | $31.71M | +375.0% | +98.2% | 4.3% | |
| Mar 2026 | $10.43M | -1.1% | -38.0% | 4.8% | |
| Mar 2026 | $10.36M | +5079.0% | +557.5% | 4.5% | |
| Mar 2026 | $1.88M | -21.6% | — | 4.6% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCT) | $6.12M | +278.8% | +109.4% | 4.2% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.